Skip to main content

Table 1 Study calendar

From: Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity

  1. aVital signs should be assessed within 30 minutes after the end of the infusion
Back to article page

Pilot and Feasibility Studies

ISSN: 2055-5784